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Summary
Through allele-segregation and loss-of-heterozygosity
analyses, we demonstrated loss of the translocation-de-
rivative chromosome 3 in five independent renal cell tu-
mors of the clear-cell type, obtained from three members
of a family in which a constitutional t(2;3)(q35;q21)was
encountered. In addition, analysis of the von Hip-
pel–Lindau gene, VHL, revealed distinct insertion, de-
letion, and substitution mutations in four of the five
tumors tested. On the basis of these results, we conclude
that, in this familial case, an alternative route for renal
cell carcinoma development is implied. In contrast to the
first hit in the generally accepted two-hit tumor-sup-
pressor model proposed by Knudson, the familial trans-
location in this case may act as a primary oncogenic
event leading to (nondisjunctional) loss of the der(3)
chromosome harboring theVHL tumor-suppressor gene.
The risk of developing renal cell cancer may be corre-
lated directly with the extent of somatic (kidney) mo-
saicism resulting from this loss.
Introduction
Renal cell carcinomas (RCCs) represent 85% of all pri-
mary renal neoplasms and, together with nephroblas-
toma, have been studied frequently at both the cytoge-
netic and the molecular level (Meloni et al. 1992; van
den Berg and Buys 1997). They constitute a heteroge-
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neous group of tumors that can be divided into different
subtypes, including the papillary and the nonpapillary
types (Meloni et al. 1992; Motzer et al. 1996; van den
Berg et al. 1997b). Papillary RCCs are characterized by
a combination of gains of chromosomes 7 and 17 and
loss of the Y chromosome. In addition, t(X;1)(p11;q21)
has repeatedly been encountered in a subset of these
tumors (Meloni et al. 1992). We and others recently
found that this translocation results in a fusion of the
transcription factor TFE3 gene, on the X chromosome,
to a novel gene, designated PRCC, on chromosome 1
(Sidhar et al 1996; Weterman et al. 1996a, 1996b). In
addition, mutations in the MET proto-oncogene on
chromosome 7 were detected in the germ lines of affected
members of papillary RCC families and in a subset of
sporadic papillary RCCs (Schmidt et al. 1997).
Nonpapillary RCCs are found mostly in the sporadic
form. Loss of heterozygosity (LOH) analysis of these
RCCs revealed that allelic losses predominantly occur in
the chromosome 3p21 region, together with losses in
either 3p25, 3p13-14, or both (van den Berg and Buys
1997). These results indicated that the corresponding
regions on 3p may harbor tumor-suppressor genes. One
of these putative tumor-suppressor genes is the von Hip-
pel–Lindau (VHL) gene, VHL, located on 3p25. Hered-
itary nonpapillary RCC is rare, is often bilateral and/or
multifocal in nature, and has a relatively early onset
(Meloni et al. 1992; Stein and Stein 1995; Motzer et al.
1996). These hereditary RCCs may develop as a con-
sequence of VHL disease, in which the VHL gene is
inactivated by mutation and/or hypermethylation
(Gnarra et al. 1994; Herman et al. 1994). Somatic mu-
tations and LOH of the VHL gene were also found in
primary sporadic RCCs (Foster et al. 1994; Gnarra et
al. 1994, 1995; Shuin et al. 1994; Zhuang et al. 1996).
Until recently, only two familial RCC cases with bal-
anced chromosomal translocations had been encoun-
tered. In the first family, a constitutional t(3;8)(p14;q24)
was found in several family members, including 10 RCC
patients, over four generations (Cohen et al. 1979; Li et
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Figure 1 Pedigree of the renal cancer family
al. 1993). In the second family, a constitutional
t(3;6)(p13;q25) was found in three consecutive genera-
tions. As yet, only the oldest member of this latter family
has developed multiple bilateral RCCs (Kovacs et al.
1989). In addition, a single sporadic RCC case has been
reported, carrying a constitutional t(3;12)(q13;q24)
(Kovacs and Hoene 1988). In both these familial and
sporadic RCC cases, the translocation-derived chro-
mosome containing the distal 3p segment was found to
be lost in the tumor tissues (Kovacs and Hoene 1988;
Kovacs et al. 1989; Li et al. 1993; Kok et al. 1997),
which supports a pivotal role for this chromosomal seg-
ment in nonpapillary RCC causation. The chromosome
3 breakpoints are different in all three cases. If these
translocations disrupt genes, therefore, they will involve
different genes. At present, only one of these
genes—FHIT, which is involved in the (3;8) transloca-
tion and maps to 3p14—has been identified (Ohta et al.
1996). However, the exact role of this gene in cancer
causation remains to be resolved (van den Berg et al.
1996, 1997a).
Recently, we identified a new familial case of RCC
(Koolen et al. 1998). Four patients, over three genera-
tions, developed nonpapillary RCCs, and one patient
was diagnosed with a squamous bladder carcinoma. Cy-
togenetic analysis revealed that all these patients (and
several unaffected members) carried a balanced
t(2;3)(q35;q21) translocation. To elucidate the role of
this novel chromosome 3 translocation in RCC devel-
opment, we performed allele-segregation, LOH, and mu-
tation analyses of various normal tissues and primary
tumor samples.
Material and Methods
Patient Material and Somatic Cell Hybrids
Paraffin-embedded tumor samples were available
(with informed consent) from patients II:1, II:7, and III:
6 (fig. 1). From patient II:7, three different samples were
obtained. One of these samples was isolated from a tu-
mor in the right kidney, which was removed after RCC
had been diagnosed in 1984, and two were isolated from
the left kidney after partial nephrectomy and multifocal
RCC diagnosis in 1995 (Koolen et al. 1998). Before
DNA extraction, tumor-containing areas were selected
via microscopic inspection. Wherever possible, adjacent
normal renal tissues were included as controls.
Blood samples from all living members of the RCC
family (except III:7) were used (with informed consent)
to generate lymphocytic cell lines after in vitro Epstein-
Barr virus (EBV) transformation. Somatic cell hybrids
were isolated after fusion of thymidine kinase–deficient
Chinese hamster A3 cells with t(2;3)-positive lympho-
cytes of patient II:7, following hypoxanthine-amino-
pterine-thymidine selection, as described elsewhere
(Geurts van Kessel et al. 1983). Approximately 80 in-
dependent clones were isolated, and their human chro-
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mosomal constitution was established through kary-
otyping and PCR screening with chromosome 2– and
chromosome 3–specific primer sets (see below). A3KE-
11C was chosen as a derivative chromosome 2 (der[2])
hybrid, A3KE-1D as a der(3) hybrid, and A3KE-34B
and A3KE-1A as normal chromosome 2– and chro-
mosome 3–containing hybrids, respectively. No other
chromosome 2 or chromosome 3 material was found to
be present in these selected hybrid lines.
DNA Isolation and PCR Analysis
Cell line–derived genomic DNAs were isolated by
means of proteinase K/SDS treatment followed by phe-
nol/chloroform extraction and ethanol precipitation.
DNA extractions from selected parts of paraffin-embed-
ded tumor samples were performed with a lysis buffer
and protein-precipitation solution (Puregene, Gentra
Systems).
PCR was performed in a volume of 25 ml containing
10 mM Tris-HCl, pH 9.0; 50 mM KCl; 1.5 mM MgCl2;
200 mM each nucleotide; 50 ng each primer; 0.25 U Taq
polymerase (Thermoperfect Integro); ∼100 ng genomic
DNA; and 0.1 ml fluorescent-labeled dUTP R110 or R6G
(Applied Biosystems, Perkin Elmer). Samples were cov-
ered with mineral oil and were amplified for 35 cycles.
Each cycle included denaturation at 94C for 30 s, an-
nealing at temperatures 5–10C below the melting tem-
perature of the primers for 45 s, and elongation at 72C
for 1 min. In the first cycle, an extra denaturation step
of 2 min was included, and, in the last cycle, elongation
was extended for 5 min. The fluorescent-labeled PCR
products were analyzed by use of 6% polyacrylamide
gels (Sequagel-6, National Diagnostics), an ABI 373A
apparatus (Applied Biosystems, Perkin Elmer), and the
GENESCAN ANALYSIS software package (Applied
Biosystems, Perkin Elmer).
The microsatellite markers used in this study were
D2S162 (Genome Database [GDB] accession number
188450), D2S144 (GDB 188238), D2S139 (GDB
188182), D2S156 (GDB 188377), and D2S172 (GDB
188529), from chromosome 2, and D3S1038 (GDB
188715), D3S1481 (GDB 197992), D3S1303 (GDB
188447), and D3S1290 (GDB 188268), from chromo-
some 3 (Smith et al. 1995; Spurr et al. 1996; van den
Berg et al. 1996). These markers were selected from the
consensus map generated at the Fifth International
Chromosome 3 Workshop (Smith et al. 1995).
Sequence Analysis
For sequence analysis of the VHL gene, five different
primer sets were used: K54 (5′ GAA ATA CAG TAA
CGA GTT GGC CTA GC 3′)/G7R72 (5′ ACC TCG GCC
TCG TCC CAG T 3′); G7F27 (5′ CCC GGG TGG TCT
GGA TCG 3′)/G7R297 (5′ ATA CGG GCA GCA CGA
CGC 3′); VHL-22-1/VHL-7 (GDB 375133); G712F2 (5′
CCT TTG CTT GTC CCG ATA GGT CA 3′)/G713R1
(5′ ACA TCA GGC AAA AAT TGA GAA CTG G 3′);
and G713FX4 (5′ CCT TGT ACT GAG ACC CTA GTC
TGC CAC T 3′)/G7R727 (5′ CAA GAC TCA TCA GTA
CCA TCA AAA GGT 3′). DNA sequences were analyzed
by use of the Ready Reaction Dye Terminator Cycle
Sequencing kit (Applied Biosystems, Perkin Elmer) and
the automated DNA sequencer ABI 373A (Applied Bios-
ystems, Perkin Elmer).
Results
Renal Cell–Cancer Family and t(2;3)(q35;q21)
A family in which four different patients over three
generations had developed nonpapillary RCC of the
clear-cell type (fig. 1) was referred to our clinic.
Cytogenetic analysis revealed that two of the patients
(II:7 and III:6) carried a constitutional balanced
t(2;3)(q35;q21) translocation (fig. 2A). In the two other
RCC cases (I:2 and II:1), carriership of the translocation
could be deduced through cytogenetic analysis of the
patients’ children (Koolen et al. 1998). Furthermore, one
squamous bladder cell carcinoma was diagnosed in the
t(2;3)(q35;q21)-positive patient II:5. The (2;3) translo-
cation was also observed in eight other family members
tested (Koolen et al. 1998). Through genealogic inves-
tigation, two additional family branches (27 first- and
second-degree relatives of both I:1 and I:2) could be
identified, but no translocation carriers were detected.
This finding suggested that the t(2;3)(q35;q21) most
likely occurred de novo in patient I:2. In this branch of
the family, the tumors developed at an earlier age than
that at which sporadic renal cancers normally develop,
and, in some cases, they were bilateral and/or multifocal
in nature (Koolen et al. 1998).
Segregation of Chromosome 2 and 3 Markers
The microsatellite markers used in this study and their
relative positions on chromosomes 2 and 3 are shown
in figure 2B. The chromosome 3 markers D3S1038 and
D3S1481 are located near two of the putative RCC-
associated tumor-suppressor loci in the regions 3p25
(VHL) and 3p14 (FHIT), respectively (van den Berg et
al. 1997b). Somatic cell hybrid analysis using the II:7-
derived lines A3KE-34B, A3KE-11C, A3KE-1A, and
A3KE-1D revealed that D3S1303 is located proximal to
the t(2;3)(q35;q21) breakpoint on chromosome 3 and
thatD3S1290 maps distal to it (figs. 2B and 3). Similarly,
on chromosome 2, the marker D2S172 could be posi-
tioned distal to the breakpoint, whereas the other mark-
ers (D2S162, D2S144, D2S139, and D2S156) were
mapped proximal to it.
In addition, by use of the same hybrid-cell panel, the
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Figure 2 A, Lymphocyte-derived partial karyotype of patient II:7, showing the normal chromosomes 2 and 3 and the translocation
derivatives der(2) and der(3). The chromosomal breakpoints are located within bands 2q35 and 3q21, respectively. B, Schematic overview of
both normal and derivative chromosomes 2 and 3 and the relative positions of the different microsatellite markers that were used in this study.
The positions of the translocation breakpoints are marked by arrows.
maternal or paternal origin of the different microsatellite
alleles on the normal chromosomes 2 and 3 and their
respective translocation derivatives could be deduced
from patient II:7, assuming that RCC patient I:2 was
also a translocation carrier (fig. 3). This microsatellite
analysis was extended to all other family members by
means of EBV-transformed lymphocytic cell lines and/
or patient-derived normal kidney tissues (data not
shown). This information was subsequently used for in-
terpretation of the LOH data obtained from the different
tumor samples.
Tumor-Associated Loss of the der(3) Chromosome
For LOH analysis, tumor areas were selected by mi-
croscopy and were subsequently isolated from paraffin
sections by microdissection. After DNA extraction, the
chromosome 2 and chromosome 3 microsatellite pat-
terns of the tumor samples were compared with those
of the normal control kidney tissues and/or correspond-
ing lymphocytic cell lines. In figure 3, some examples of
such an LOH analysis are shown. One of the tumors
isolated from patient II:7 (T95.1) was assayed for chro-
mosome 2 markers D2S139 and D2S172 and chro-
mosome 3 markers D3S1303 and D3S1290, located
proximal and distal to the t(2;3)(q35;q21) breakpoints
on chromosomes 2 and 3, respectively (fig. 2B). Micro-
satellite profiles from tumor tissue, normal tissue, and
II:7-derived somatic cell hybrids were compared. The
alleles located on der(3) (D2S172:279 and D3S1303:
209) exhibited a significant loss in the tumor tissue as
compared with the normal tissue and/or the somatic cell
hybrids (marked by LOH in fig. 3). Such losses can best
be explained by a loss of the der(3) chromosome in the
original tumor. No complete LOH was observed in the
tumor DNA, which suggests that the tumor sample was
still contaminated with normal cells in spite of micro-
dissection prior to DNA extraction. No LOH was ob-
served for the microsatellite markers D2S139 and
D3S1290, located proximal to the breakpoint on chro-
mosome 2 and distal to the breakpoint on chromosome
3, respectively (fig. 3). This result may indicate that both
the normal copies of chromosomes 2 and 3 and the
translocation-derived der(2) chromosome were retained
in the original tumor sample. Similar results were ob-
tained with all other (informative) markers and tumors
included in this study. A summary of these data is pro-
vided in table 1. After combining the chromosome 2 and
3 segregation data (above) with the LOH data from
patients II:1 and III:6 (table 1), we conclude that in these
cases, too, the der(3) chromosome must be lost in the
tumors.
VHL Gene Mutations in the RCCs
On the basis of the observed loss of the der(3) chro-
mosome and, as a consequence, the loss of one copy of
the VHL gene in the different tumor samples examined
within this family, we performed mutation analysis on
the remaining VHL gene in the tumor-derived DNAs by
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Figure 3 Tumor T95.1 (patient II:7)–derived allele plots of four different markers located on chromosomes 2 and 3. Allele patterns of
the tumor tissue were compared with those of normal tissue and II:7-derived somatic cell hybrids containing chromosome 2, chromosome 3,
and the respective translocation derivatives. A, Marker D2S139, located proximal to the breakpoint on chromosome 2. B, Marker D2S172,
located distal to the breakpoint on chromosome 2. C, Marker D3S1303, located proximal to the breakpoint on chromosome 3. D, Marker
D3S1290, located distal to the breakpoint on chromosome 3.
direct sequencing, using exon 1–, exon 2–, and exon
3–specific primer sets. Again, normal kidney–derived
and/or lymphocytic cell line–derived DNAs were in-
cluded as controls (fig. 4). In one of the tumors (T95.1)
of patient II:7, isolated from the right kidney in 1995,
sequence analysis revealed a single–base-pair insertion
at position 535 (535insC) of exon 1. In the second tumor
(T95.2) isolated from the same kidney at the same time,
a deletion of 10 bp at position 373 (373del10) was ob-
served, again in the first exon of the gene. In the tumor
(T84) isolated from the left kidney of this same patient
in 1984, no mutations were detected in either of the
exons tested. In the RCC of patient II:1, a 19-bp deletion
(722del19) was found in the third exon, and, in the
tumor of patient III:6, a single–base-pair substitution,
P86H(CrA), was observed in, again, the first exon. All
the observed VHL mutations are located in the muta-
tion–hot-spot regions described in the literature, and
they lead to frameshifts and/or substitutions that result
in a loss of function of the encoded proteins. The num-
bering of the nucleotide positions mentioned corre-
sponds to the GenBank accession number L15409 se-
quence and to the nomenclature described by Beaudet
and Tsui (1993).
Discussion
We have detected a novel familial case of renal cell
cancer with a t(2;3)(q35;q21) chromosome transloca-
tion. Patient II:7 was of particular interest, since three
Figure 4 A, Schematic representation of the VHL gene, including the nucleotide and codon (in parentheses) numbers (above) and the
primer sets that were used for mutation analysis (below). The regions underlined with solid bars are known mutation hot spots. B, VHL gene
mutations found in four tumor DNAs of three RCC patients (II:1, II:7, and III:6). Since the tumor samples were contaminated with normal
cells, double sequence patterns are seen after the insertion/deletion mutations.
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Table 1
Summary of Chromosome 2 and Chromosome 3 LOH Results in
Five RCCs from Patients II:1, II:7, and III:6
CHROMOSOME
AND
POLYMORPHIC
MARKER
RCC IN PATIENT (TUMOR)a
II:1
II:7
(T84)
II:7
(T95.1)
II:7
(T95.2) III:6
2:
D2S162     
D2S144     
D2S139     
D2S156     
D2S172     
3:
D3S1038     
D3S1481     
D3S1303     
D3S1290     
a A minus sign () indicates LOH negative, and a plus sign ()
indicates LOH positive.
tumors could be obtained independently, from different
anatomical locations, at two different occasions, with a
time lapse of 11 years (1984–95). Lymphocyte-derived
somatic cell–hybrid and microsatellite-marker analyses
unambiguously demonstrated that, in all three tumors,
the translocation-derived der(3) chromosome was lost.
Subsequent segregation and LOH analyses revealed that
the der(3) chromosome was also lost in two additional
tumors derived from patients II:1 and III:6. Sequence
analysis of the VHL gene revealed distinct mutations in
four of the five tumors tested. All these mutations re-
sulted in a loss of function. These data indicate that the
different tumors that were studied developed indepen-
dently (and not as metastases of a primary tumor—in
particular, the three tumors of patient II:7) and that,
most likely, in all cases, loss of the der(3) chromosome
has occurred as a primary event. As a consequence of
this scenario, the different VHL gene mutations should
be considered as secondary events.
Translocations involving chromosome 3 have fre-
quently been encountered in sporadic RCCs and in some
(three, to date) familial RCC cases (Cohen et al. 1979;
Kovacs and Hoene 1988; Kovacs et al. 1989; Li et al.
1993). Kovacs and Kung (1991) developed an alterna-
tive model for RCC development in which, in contrast
to the generally accepted two-hit tumor-suppressor
model put forward by Knudson (1993, 1996), familial
translocations may act as primary oncogenic events.
They proposed that reciprocal translocations involving
chromosome 3 could, somatically, result in random non-
disjunctional loss of the derivative chromosome carrying
the 3p segment harboring putative tumor-suppressor loci
such as VHL (Kovacs and Frisch 1989; Kovacs and
Kung 1991; Kovacs 1993). Subsequent tumor formation
would result from mutation of the remaining tumor-
suppressor allele. Our results are in full support of this
model and provide experimental evidence for it. Non-
disjunctional loss may occur in any cell at any stage of
(embryonic kidney) development. Accordingly, the risk
of developing renal cell cancer may be correlated directly
to the extent of somatic mosaicism resulting from this
(random) loss. This latter notion nicely explains the rel-
atively wide range in age at RCC onset observed in this
family (e.g., patients II:3 and III:6; Koolen et al. 1998).
The proposed nondisjunctional loss may be due to an
increased genetic instability, possibly caused by
t(2;3)(q35;q21) itself. Therefore, we also searched for
microsatellite and/or mitotic anomalies. Microsatellite
instability in tumor tissues was not observed for any of
the markers tested in this work. Mitotic errors were eval-
uated in 300 lymphocyte-derived methaphase spreads of
three different translocation carriers, but no significant
increases in abnormalities could be observed. Other tis-
sues were not investigated.
VHL gene mutations have been reported to occur fre-
quently (in 33%–57% of cases) in sporadic RCCs and
in two of the four familial t(3;8)-associated RCCs an-
alyzed (Gnarra et al. 1994; Knudson 1995; Schmidt et
al. 1995). All these mutations were found to be located
within known VHL mutation hot spots (Foster et al.
1994; Gnarra et al. 1994; Zbar et al. 1996; Decker et
al. 1997). In one of the current tumors (T84), no mu-
tations could be detected in either of the exons tested.
In this case, mutations may still be present in the VHL
promoter region, or, alternatively, the VHL gene may be
inactivated in the tumor via hypermethylation (Herman
et al. 1994). Obviously, mutations in other putative tu-
mor-suppressor gene(s) on 3p may also be present (van
den Berg and Buys 1997). These latter possibilities re-
main to be tested.
Taken together, our results support the RCC devel-
opment model of Kovacs and Kung (1991) as an alter-
native route for multistep tumorigenesis. Currently, we
are isolating the t(2;3)(q35;q21) breakpoint to find out
whether, analogous to FHIT, a gene can be identified at
or near the breakpoint in either chromosome 2 or chro-
mosome 3.
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